![Arthur Michael Feldman](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Arthur Michael Feldman
Fondateur chez CardioKine, Inc.
Postes actifs de Arthur Michael Feldman
Sociétés | Poste | Début | Fin |
---|---|---|---|
CardioKine, Inc.
![]() CardioKine, Inc. Pharmaceuticals: MajorHealth Technology CardioKine, Inc. develops drugs and pharmaceuticals for the treatment and prevention of heart failure. The company was founded by Arthur Michael Feldman, James Mervis, Paul-Andre de Lame and Michael Juliano in 2004 and is headquartered in Pittsburgh, PA. | Directeur/Membre du Conseil | 04/06/1998 | - |
Fondateur | 04/06/1998 | - | |
President | - | - | |
Sidney Kimmel Medical College | Président | - | - |
Renovacor Holdings, Inc.
![]() Renovacor Holdings, Inc. BiotechnologyHealth Technology Renovacor, Inc. operates as a preclinical stage biopharmaceutical company focused on developing transformative gene therapy based treatments for cardiovascular disease. The company is headquartered in Philadelphia, PA. | Directeur/Membre du Conseil | - | - |
Fondateur | - | - |
Historique de carrière de Arthur Michael Feldman
Anciens postes connus de Arthur Michael Feldman
Sociétés | Poste | Début | Fin |
---|---|---|---|
TouchStone Research, Inc.
![]() TouchStone Research, Inc. Miscellaneous Commercial ServicesCommercial Services TouchStone Research, Inc. (formerly known as Clinical Cardiovascular Research LLC) provides contract research services to pharmaceutical and medical device companies developing cardiovascular therapies. Its services include product development consulting, clinical trial design & execution, data analysis & report writing and other services to help health care companies move their heart-helping product candidates through the development & regulatory approval process. It was founded in 1997 and is headquartered in Gaithersburg, MD | Directeur/Membre du Conseil | - | 23/10/2007 |
RENOVACOR, INC. | Fondateur | 07/06/2013 | - |
The Johns Hopkins University | Directeur/Membre du Conseil | - | - |
Formation de Arthur Michael Feldman
Gettysburg College | Undergraduate Degree |
Louisiana State University | Graduate Degree |
University of Maryland | Doctorate Degree |
Statistiques
Internationale
Etats-Unis | 10 |
Opérationnelle
Director/Board Member | 4 |
Founder | 3 |
Undergraduate Degree | 1 |
Sectorielle
Consumer Services | 6 |
Health Technology | 4 |
Commercial Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Entreprise privées | 4 |
---|---|
TouchStone Research, Inc.
![]() TouchStone Research, Inc. Miscellaneous Commercial ServicesCommercial Services TouchStone Research, Inc. (formerly known as Clinical Cardiovascular Research LLC) provides contract research services to pharmaceutical and medical device companies developing cardiovascular therapies. Its services include product development consulting, clinical trial design & execution, data analysis & report writing and other services to help health care companies move their heart-helping product candidates through the development & regulatory approval process. It was founded in 1997 and is headquartered in Gaithersburg, MD | Commercial Services |
CardioKine, Inc.
![]() CardioKine, Inc. Pharmaceuticals: MajorHealth Technology CardioKine, Inc. develops drugs and pharmaceuticals for the treatment and prevention of heart failure. The company was founded by Arthur Michael Feldman, James Mervis, Paul-Andre de Lame and Michael Juliano in 2004 and is headquartered in Pittsburgh, PA. | Health Technology |
Renovacor Holdings, Inc.
![]() Renovacor Holdings, Inc. BiotechnologyHealth Technology Renovacor, Inc. operates as a preclinical stage biopharmaceutical company focused on developing transformative gene therapy based treatments for cardiovascular disease. The company is headquartered in Philadelphia, PA. | Health Technology |
Renovacor, Inc.
![]() Renovacor, Inc. BiotechnologyHealth Technology Renovacor, Inc. operates as a clinical stage gene therapy company. It researches and develops AAV-based gene therapies for BAG3 gene mutation-associated diseases. Its therapeutic focus is on cardiovascular diseases. The company was founded by Arthur Michael Feldman on June 7, 2013 and is headquartered in Cambridge, MA. | Health Technology |
- Bourse
- Insiders
- Arthur Michael Feldman
- Expérience